Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine

Antiviral Therapy

Volumn 6, Issue 1, 2001, Pages 41-46

  Rusconi, Stefano ^a   La Seta Catamancio, Simona ^a   Citterio, Paola ^a   Bulgheroni, Elisabetta ^a   Kurtagic, Semir ^a   Galazzi, Morena ^a   Croce, Francesco ^a   Moroni, Mauro ^a   Galli, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE;

EID: 0035292151     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD & the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338:853-860.
2. Richman DD. Drug resistance and its implications in the management of HIV infection. Antiviral Therapy 1997; 2 (Suppl. 4):41-58.
3. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, Gu K, Song Q, Manne J, Islam S, Castriota G & Prasad VR. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271:1282-1285.
4. Eron J, Benoit S, Jemsek J, MacArthur R, Santana J, Quinn J, Kurtzkes D, Fallon M & Rubin M for the North American HIV Working Party. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New England Journal of Medicine 1995; 333:1662-1669.
5. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H & Lamivudine European HIV Working Group. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-naive patients. A randomized controlled comparison with zidovudine monotherapy. Journal of the American Medical Association 1996; 276:118-125.
6. Staszewski S, Miller V, Rehmet S, Stark T, De Cree' J, De Brabander M, Peeters M, Andries K, Moeremans M, De Raeymaeker M, Pierce G, Van Der Broeck R, Verbiest W & Stoffels P. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 1996; 10:F1-F7.
7. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA & Rubin M. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10:975-981.
8. Miller V, Sturmer M, Staszewski S, Groschel B, Hertogs K, de Bethune M-P, Pauwels R, Harrigan PR, Bloor S, Kemp SD & Larder BA. The M184V mutation in HIV-1 reverse transriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998; 12:705-712.
9. Larder B, Staszewski S, Pauwels R, de Bethune MP, Van den Eynde C, Larder BA, Harrigan PR, Tisdale M, Kemp SD, Bloor S, Stone C, Kohli A, Myers R, Mellors J & Shi C for the FASP Resistance Study Group. Patterns of drug resistance in HIV-1 isolates from patients treated with AZT and 3TC. Antiviral Therapy 1996; 1 (Suppl. 1):38.
10. Miller V, Gute P, Carlebach A, Nisius G, Leder T, Rottmann C, Sturmer M, Hertogs K, Larder BA & Staszewski S. Baseline resistance and virological response to mega-HAART salvage therapies. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 31 January - 4 February 1999. Abstr. 130.
11. Katlama C, Duvivier C, Mouroux M, Legrand M, Chiesa E, Schneider L, Ait-Mohand H, Agher R, Coutellier A, Fievet MH, Race E, Clavel F & Calvez V. GIGHAART: a rescue therapy for HIV patients with multiple HAART failures. Antiviral Therapy 1999; 4 (Suppl. 1):77.
12. Montaner JSG, Harrigan R, Raboud J, Jahnke N, Hoog RS, Yip B & O'Shaughnessy MV. Multidrug rescue therapy (MDRT) in two cohorts of HIV+ individuals. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January - 2 February 2000. Abstr. 536.
13. Merrill DP, Moonis M, Chou T & Hirsch MS. Lamivudine (3TC) or stavudine (d4T) in two- and three-drug combinations against HIV-1 replication in vitro. Journal of Infectious Diseases 1996; 137:355-364.
14. Rusconi S, De Pasquale MP, Milazzo L, Moscatelli G, Bulgheroni E, Citterio P, d'Arminio-Monforte A, Moroni M & Galli M. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open label trial. Antiviral Therapy 1997; 2:41-48.
15. Rusconi S, De Pasquale MP, Milazzo L, Kurtagic S, Bulgheroni E, Citterio P, Galazzi M, La Seta Catamancio S & Galli M. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant human immunodeficiency virus type 1 (HIV-1) isolate after discontinuation of in vitro lamivudine drug pressure. Antiviral Therapy 1998; 3:203-207.
16. Shafer RW, Winters MA, Iversen AKN & Mengan TC. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Antimicrobial Agents & Chemotherapy 1996; 40:2887-2890.
17. Shafer RW, Kozal MJ, Winters MA, Iversen AKN, Katzenstein DA, Ragni MV, Meyer WA III, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S & Merigan TC. Combination therapy with zidovudine and didanosine selects for drug resistant HIV-1 strains with unique patterns of pol gene mutations. Journal of Infectious Diseases 1994; 169:722-729.
18. Najera I, Holguin A, Quinones-Mateu ME, Munoz-Fernandez ME, Najera R, Lopez-Galindez C & Domingo E. pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. Journal of Virology 1995; 69:23-31.
19. Drusano GL, Bilello JA, Stein DS, Nessly M, Meibohm A, Emini EA, Deutsch P, Condra J, Chodakewitz J & Holder DJ. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. Journal of Infectious Diseases 1998; 178:360-367.
20. Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, Moroni M, Galli M & d'Arminio-Monforte A. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrobial Agents & Chemotherapy 2000; 44:1328-1332.
21. Chou T-C & Talalay P. Quantitative analysis of dose effect relationships: the combined effect of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984; 22:27-55.
22. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, Katzenstein DA & Merigan TC. A 6-base-pair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Journal of Clinical Investigation 1998; 102:1769-1775.
23. Larder BA, Kemp SD & Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
24. Gass RJA, Shugarts D, Young R, Allen M, Rosandich M & Kuritzkes DR. Emergence of dual resistance to zidovudine and lamivudine in clinical HIV-1 isolates from patients receiving zidovudine/lamivudine combination therapy. Antiviral Therapy 1998; 3:97-102.
25. Miller V, Phillips A, Rottmann C, Staszewski S, Pauwels R, Hertogs K, de Bethune M-P, Kemp SD, Bloor S, Harrigan PR & Larder BA. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. Journal of Infectious Diseases 1998; 177:1521-1532.
26. Rusconi S, De Pasquale MP, Milazzo L, Bulgheroni E, Citterio P, Kurtagic S, d'Arminio-Monforte A & Galli M. In vitro effects of a continuous pressure with zidovudine (ZDV) and lamivudine on a ZDV-resistant HIV-1 isolate. AIDS 1997; 11:1406-1410.
27. Hertogs K, Bloor S, De Vroey V, Van den Eynde C, Dehertogh P, Van Cauwenberge A, Sturmer M, Alcorn T, Wegner S, Houtte MV, Miller V & Larder BA. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers resistance in the absence of mutation 184V. Antimicrobial Agents & Chemotherapy 2000; 44:568-573.
28. Coakley EP, Gillis JM & Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000; 14:F9-F15.
29. Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin J-L, Massip P, Puel J, Fleury H & Segondy M for the STADI Group. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. AIDS 1999; 13:1705-1709.